These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 32651063)

  • 1. Next-Generation Sequencing Identified a Novel Crizotinib-Sensitive PLB1-ALK Rearrangement in Lung Large-Cell Neuroendocrine Carcinoma.
    Wang S; Wu X; Zhao J; Chen H; Zhang Z; Wang M; Xu C; Wang Y; Wang L; He Z; Wang Q
    Clin Lung Cancer; 2021 May; 22(3):e366-e370. PubMed ID: 32651063
    [No Abstract]   [Full Text] [Related]  

  • 2. Large Cell Neuroendocrine Carcinoma Harboring an Anaplastic Lymphoma Kinase (ALK) Rearrangement with Response to Alectinib.
    Hayashi N; Fujita A; Saikai T; Takabatake H; Sotoshiro M; Sekine K; Kawana A
    Intern Med; 2018 Mar; 57(5):713-716. PubMed ID: 29151522
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of ALK Immunohistochemistry for Optimal Therapeutic Strategy of Pulmonary Large-cell Neuroendocrine Carcinoma and Identification of a Novel
    Shimizu N; Akashi Y; Fujii T; Shiono H; Yane K; Kitahara T; Ohta Y; Kakudo K; Wakasa T
    Anticancer Res; 2019 Jan; 39(1):413-420. PubMed ID: 30591488
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Next generation sequencing reveals a novel ALK G1128A mutation resistant to crizotinib in an ALK-Rearranged NSCLC patient.
    Ai X; Niu X; Chang L; Chen R; Ou SI; Lu S
    Lung Cancer; 2018 Sep; 123():83-86. PubMed ID: 30089600
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A case of large-cell neuroendocrine carcinoma harboring an EML4-ALK rearrangement with resistance to the ALK inhibitor crizotinib.
    Omachi N; Shimizu S; Kawaguchi T; Tezuka K; Kanazu M; Tamiya A; Asami K; Okishio K; Kitaichi M; Atagi S
    J Thorac Oncol; 2014 Jun; 9(6):e40-2. PubMed ID: 24828670
    [No Abstract]   [Full Text] [Related]  

  • 6. Heterogeneous Tumor-Immune Microenvironments between Primary and Metastatic Tumors in a Patient with
    Tashiro T; Imamura K; Tomita Y; Tamanoi D; Takaki A; Sugahara K; Sato R; Saruwatari K; Sakata S; Inaba M; Ushijima S; Hirata N; Sakagami T
    Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33352665
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CUX1-ALK, a Novel ALK Rearrangement That Responds to Crizotinib in Non-Small Cell Lung Cancer.
    Zhang M; Wang Q; Ding Y; Wang G; Chu Y; He X; Wu X; Shao YW; Lu K
    J Thorac Oncol; 2018 Nov; 13(11):1792-1797. PubMed ID: 30010043
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Large-cell neuroendocrine carcinoma of the lung harboring EGFR mutation and responding to gefitinib.
    De Pas TM; Giovannini M; Manzotti M; Trifirò G; Toffalorio F; Catania C; Spaggiari L; Labianca R; Barberis M
    J Clin Oncol; 2011 Dec; 29(34):e819-22. PubMed ID: 22042963
    [No Abstract]   [Full Text] [Related]  

  • 9. MET Alterations Are a Recurring and Actionable Resistance Mechanism in ALK-Positive Lung Cancer.
    Dagogo-Jack I; Yoda S; Lennerz JK; Langenbucher A; Lin JJ; Rooney MM; Prutisto-Chang K; Oh A; Adams NA; Yeap BY; Chin E; Do A; Marble HD; Stevens SE; Digumarthy SR; Saxena A; Nagy RJ; Benes CH; Azzoli CG; Lawrence MS; Gainor JF; Shaw AT; Hata AN
    Clin Cancer Res; 2020 Jun; 26(11):2535-2545. PubMed ID: 32086345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heterogeneous responses and resistant mechanisms to crizotinib in ALK-positive advanced non-small cell lung cancer.
    Kang J; Chen HJ; Zhang XC; Su J; Zhou Q; Tu HY; Wang Z; Wang BC; Zhong WZ; Yang XN; Chen ZH; Ding Y; Wu X; Wang M; Fu JG; Yang Z; Zhang X; Shao YW; Wu YL; Yang JJ
    Thorac Cancer; 2018 Sep; 9(9):1093-1103. PubMed ID: 29978950
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sequential Therapy with Crizotinib and Alectinib in ALK-Rearranged Non-Small Cell Lung Cancer-A Multicenter Retrospective Study.
    Ito K; Hataji O; Kobayashi H; Fujiwara A; Yoshida M; D'Alessandro-Gabazza CN; Itani H; Tanigawa M; Ikeda T; Fujiwara K; Fujimoto H; Kobayashi T; Gabazza EC; Taguchi O; Yamamoto N
    J Thorac Oncol; 2017 Feb; 12(2):390-396. PubMed ID: 27498387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment Optimization for Brain Metastasis from Anaplastic Lymphoma Kinase Rearrangement Non-Small-Cell Lung Cancer.
    Wang W; Sun X; Hui Z
    Oncol Res Treat; 2019; 42(11):599-606. PubMed ID: 31527380
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Resistance profiles of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced non-small-cell lung cancer: a multicenter study using targeted next-generation sequencing.
    Lin YT; Chiang CL; Hung JY; Lee MH; Su WC; Wu SY; Wei YF; Lee KY; Tseng YH; Su J; Chung HP; Lin CB; Ku WH; Chiang TS; Chiu CH; Shih JY
    Eur J Cancer; 2021 Oct; 156():1-11. PubMed ID: 34392186
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The clinical responses of TNIP2-ALK fusion variants to crizotinib in ALK-rearranged lung adenocarcinoma.
    Feng T; Chen Z; Gu J; Wang Y; Zhang J; Min L
    Lung Cancer; 2019 Nov; 137():19-22. PubMed ID: 31521978
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Favorable predictors for survival in advanced ALK-positive non-small cell lung cancer patients beyond crizotinib resistance.
    Xu H; Yang G; Yang L; Yang Y; Ma D; Li J; Hao X; Xing P; Wang Y
    Thorac Cancer; 2019 May; 10(5):1096-1102. PubMed ID: 30920172
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Attenuated isolated 3' signal: A highly challenging therapy relevant ALK FISH pattern in NSCLC.
    Smuk G; Pajor G; Szuhai K; Morreau H; Kocsmár I; Kocsmár É; Pajor L; Kajtár B; Sárosi V; Lotz G; Tornóczky T
    Lung Cancer; 2020 May; 143():80-85. PubMed ID: 32272316
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anaplastic lymphoma kinase expression in small-cell lung cancer.
    Kondoh C; Horio Y; Hayashi Y; Ebi H; Hida T; Hasegawa Y; Yatabe Y
    Histopathology; 2019 Jul; 75(1):20-28. PubMed ID: 30790327
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Next-generation Sequencing Identified a Novel WDPCP-ALK Fusion Sensitive to Crizotinib in Lung Adenocarcinoma.
    He Z; Wu X; Ma S; Zhang C; Zhang Z; Wang S; Yu S; Wang Q
    Clin Lung Cancer; 2019 Sep; 20(5):e548-e551. PubMed ID: 31281052
    [No Abstract]   [Full Text] [Related]  

  • 19. Acquired Resistance Mutations to ALK Inhibitors Identified by Single Circulating Tumor Cell Sequencing in
    Pailler E; Faugeroux V; Oulhen M; Mezquita L; Laporte M; Honoré A; Lecluse Y; Queffelec P; NgoCamus M; Nicotra C; Remon J; Lacroix L; Planchard D; Friboulet L; Besse B; Farace F
    Clin Cancer Res; 2019 Nov; 25(22):6671-6682. PubMed ID: 31439588
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Alectinib and mixed large cell neuroendocrine carcinoma of the lung.].
    Hegedűs F; Sükösd F; Tiszlavicz L; Furák J; Pálföldi R; Fejes Z; Zombori T
    Orv Hetil; 2023 Apr; 164(14):548-554. PubMed ID: 37031440
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.